North America Startup Funding Rounds
Startups raising capital across North America. Compare the businesses, funding stages and investors active in the region.
- Rounds
- 2,308 Jan 1 – Oct 25, 2026
- Disclosed funding
- $251.5B 1914 disclosed amounts
- Median round
- $23.3M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| P PaperCompany profile Design platform for the agentic era, enabling designers and engineers to collaborate through a shared language. Design platform for the agentic era, enabling designers and engineers to collaborate through a shared language. | $34M | Series A | AI | United States | Investors | |
| WF Developer and manufacturer of advanced solid oxide fuel cell systems. | Undisclosed | Undisclosed | Climate tech | United States | Investors Undisclosed | |
 AbstractCompany profile Streaming security operations that detect threats in motion and route data across an organisation’s tools. Streaming security operations that detect threats in motion and route data across an organisation’s tools. | $25M | Undisclosed | Cybersecurity | United States | Investors | |
| CH Automates the financial infrastructure of American healthcare | $120M | Series DSeries C+ | Healthtech | United States | Investors | |
| TB Transcripta BioCompany profile AI-powered drug discovery company developing treatments for neurological and neuromuscular diseases AI-powered drug discovery company developing treatments for neurological and neuromuscular diseases | $24M | Series A | Biotech | United States | Investors | |
| P PawPay turns any policy into pet insurance that pays vet directly | Undisclosed | Undisclosed | Fintech | United States | Investors | |
| CT Crystalys TherapeuticsCompany profile Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout | $130M | Series B | Biotech | United States | Investors | |
| NB N-Zyme BiomedicalCompany profile Developing first-in-class therapies targeting pepsin for reflux disease Developing first-in-class therapies targeting pepsin for reflux disease | $4.6M | Series A | Biotech | United States | Investors Undisclosed | |
| HE Health EndeavorsCompany profile Health Endeavors provides AI-driven care management tools for accountable care organizations Health Endeavors provides AI-driven care management tools for accountable care organizations | Undisclosed | Growth | Healthtech | United States | Investors | |
| PL Petra LabsCompany profile End-to-end AEO partner for enterprise brands, combining software with hands-on execution End-to-end AEO partner for enterprise brands, combining software with hands-on execution | $5.2M | Seed | Enterprise software | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1Y Combinator (YC)
BioStack, Tractian, Blacksmith
134rounds3led - 2Andreessen Horowitz (a16z)
ASI, Eka Robotics, Town
98rounds19led - 3General Catalyst
Tractian, Different, Baba
70rounds7led - 4Alumni Ventures
Maxinsights, Daytona, Chariot Claims
60rounds0led - 5Khosla Ventures
Arda Industries, Tolan
59rounds6led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.